Education
About Us
Working with TipRanks
Follow Us
Autonomix Medical, Inc. (AMIX)
NASDAQ:AMIX
AMIX Stock Chart & Stats
$0.39
-$0.14(-4.75%)
At close: 4:00 PM EST
$0.39
-$0.14(-4.75%)
Day’s Range― - ―
52-Week Range$0.34 - $2.82
Previous CloseN/A
Volume72.00K
Average Volume (3M)456.51K
Market Cap
$4.51M
Enterprise Value-$7.83M
Total Cash (Recent Filing)$9.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.53
Shares Outstanding11,409,344
10 Day Avg. Volume742,337
30 Day Avg. Volume456,513
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.37
Enterprise Value/Market Cap-1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit137.37
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$2.00Price Target Upside412.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressionProgress in the device's clinical development supports advancement toward key regulatory milestones, which could boost investor confidence if pivotal data and filings proceed as planned.
Pipeline Expansion And Market OpportunityFollow-on studies evaluating additional visceral cancers and earlier-stage pancreatic cancer could meaningfully broaden the addressable market and long-term revenue potential if clinical benefits are demonstrated.
Therapeutic Differentiation From OpioidsThe microchip-based platform's potential to manage cancer-related pain without opioid-like adverse effects may differentiate the therapy and increase adoption interest across pain-treatment markets.
Bears Say
Cash Burn And Financing RiskPre-revenue status combined with operating expenses running above expectations indicates ongoing cash burn that may necessitate dilutive financing, increasing liquidity risk for investors.
Share Dilution From Capital RaisesAnalysts expect a capital raise that would dilute existing shares and reduce per-share value, creating downward pressure on the stock until dilution is addressed.
Valuation Sensitivity To Funding And Trial OutcomesLowered price targets reflect sensitivity of the company's valuation to financing outcomes and clinical milestones, meaning funding shortfalls or trial setbacks could prompt further downside in the stock.
Autonomix Medical, Inc. News
AMIX FAQ
What was Autonomix Medical, Inc.’s price range in the past 12 months?
Autonomix Medical, Inc. lowest stock price was $0.34 and its highest was $2.82 in the past 12 months.
What is Autonomix Medical, Inc.’s market cap?
Autonomix Medical, Inc.’s market cap is $4.51M.
When is Autonomix Medical, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Autonomix Medical, Inc.’s earnings last quarter?
Currently, no data Available
Is Autonomix Medical, Inc. overvalued?
According to Wall Street analysts Autonomix Medical, Inc.’s price is currently Undervalued.
Does Autonomix Medical, Inc. pay dividends?
Autonomix Medical, Inc. does not currently pay dividends.
What is Autonomix Medical, Inc.’s EPS estimate?
Autonomix Medical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Autonomix Medical, Inc. have?
Autonomix Medical, Inc. has 11,409,344 shares outstanding.
What happened to Autonomix Medical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Autonomix Medical, Inc.?
Currently, no hedge funds are holding shares in AMIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Autonomix Medical, Inc.
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
AMIX Stock 12 Month Forecast
Average Price Target
$2.00
▲(412.82% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.09% Mutual Funds
0.10% Other Institutional Investors
99.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---